2Vienken J.How can liver toxins be removed?Filtration and adsorption with the Prometheus system[J].Ther Apher Dial,2006,10(2):125-131.
3Brouns R,De Deyn PP.Neurological complications in renal failure[J].Clinical Neurology and Neuresurgery,2004,107:1-16.
4Krishnan AV.Uremic neuropathy:clinical features and new pathophysiological insights[J].Muscle Nerve,2007,35(3):273-290.
5Hamid Nasril,Azar Baradaran Z,Amir Said Alizadeh Naderi.Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis[J].Acta Medica Austliaca,2004,31(3):67-72.
6Gwidon Polak,Strozecki,Grzegorz Grzesk,et al.Effect of parathormone on heart rate variability in hemodialysis patients[J].Autonomic Neuroscience:Basic and Clinical,2004,115:94-98.
7THOMAS R,RILEY III,M D,et al.Preventive Strategies in Chronic Liver Disease:Part Ⅰ.Alcohol.Vaccines,Toxic Medications and Supplements,Diet and Exercise[J].Am Fam Physician,2001,64(9):1555-1561.
8Shiomi S, Masaki K, Habu D, et al. Calcitriol for bone disease in patients with cirrhosis of the liver[J]. J Grastroenterol Hepatol, 1999,14(6) ~ 547 - 552.
9Heathc O,Te J.Osteoporosis in chronic liver disease[J].Curr Gastroenterol Rep,1999,1(6):455-458.
10Shiomi S,Nishiguchi S,Kurooka H,et al.Cyclical etidronate for treatment of.osteopenia in patients with cirrhosis of the liver[J].Hepatol Res,2002,22(2):102-106.
